Older adults aged 60 years or older are among the populations at highest risk of developing RSV
, a highly-contagious, potentially life-threatening respiratory infection.
The FDA Breakthrough Therapy Designation was based on clinical data with Janssen's prophylactic RSV
senior vaccine that may demonstrate substantial improvement compared to available standard of care on a clinically significant endpoint(s).2
The latest report by Market Research Future (MRFR) states that the Respiratory Syncytial Virus (RSV
) market is all set to gain substantial traction by accruing gigantic revenues by 2023.
The CARESS investigators analyzed 12 years' data on respiratory hospitalizations from among palivizumab-prophylaxed patients (including specific data on RSV
when patients were tested for RSV
per standard of care).
China has a high burden of RSV
infection (4), but RSV
surveillance in this country is less established, and implementation of diagnostic tests is limited.
Children aged <5 years accounted for a decreasing percentage of reported cases in each successive RSV
season from 2013-14 to 2016-17 (89%, 84%, 82%, and 78%) (Table), while the percentage of cases in persons aged [greater than or equal to] 65 years increased in each successive season (4%, 6%, 9%, and 11%) (chi-squared test for trend, p<0.001).
Bronchiolitis or viral pneumonia is the primary manifestation of RSV
Although there are geographic differences, both subgroups are generally in association in RSV
Each year, influenza viruses cause illness in millions of cases associated with various respiratory syndromes and approximately 500,000 deaths.6 Globally, about 20% of children and 5% of adults develop symptomatic influenza each year.7 Similarly RSV
is associated with 4090% of bronchiolitis cases in children less than 5 years of age and 50% of pneumonia cases in children less than 2 years of age.8 Therefore, respiratory virus infections represent a major public health problem because of their worldwide occurrence, ease of spread in the community and considerable morbidity and mortality.
Data showed that RSV
infection occurred throughout the studied months.
Results: BAP increased dose dependently with RSV
(R = 0.471, P c.001), resulting in a significantly greater increase in BAP in the RSVhigh group compared with placebo at all time-points (week 4, 16.4 [+ or -] 4.2%, P < .001; week 8, 16.5 [+ or -] 4.1%, P < .001; week 16, 15.2 [+ or -] 3.7%, P < .001).
This globally-distributed pathogen contains a non-segmented, negative-sense ribonucleic acid (RNA) with a genomic organization similar to that of RSV
infections can lead to other more serious illnesses, added.
Respiratory syncytial virus (RSV
) is the major cause of acute lower respiratory tract infections in young children, but very little is known about its epidemiology and circulating genotypes in Pakistan.